Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder : A preliminary study

Autor: Rakesh K Chadda, Mamta Sood, Aniruddha Basu, Ritushree Kukreti, Harpreet Kaur
Rok vydání: 2015
Předmět:
Adult
Male
medicine.medical_specialty
Genotype
rs6311
Rs6313
lcsh:Medicine
Citalopram
Pharmacology
Polymorphism
Single Nucleotide
General Biochemistry
Genetics and Molecular Biology
serotonin transporter (SLC6A4) polymorphism
Gene Frequency
Internal medicine
mental disorders
medicine
Humans
Escitalopram
Genetic Predisposition to Disease
Receptor
Serotonin
5-HT2A
Genetic Association Studies
rs6295
Serotonin transporter
pharmacogenetics
Serotonin Plasma Membrane Transport Proteins
Depressive Disorder
Major
HTR2A) - serotonin transporter (SLC6A4) polymorphism
biology
business.industry
Antidepressant response
lcsh:R
General Medicine
Middle Aged
medicine.disease
Receptor
Serotonin
5-HT1A
biology.protein
Major depressive disorder
Antidepressant response - pharmacogenetics - serotonin receptor polymorphism (HTR1A
Original Article
Female
serotonin receptor polymorphism (HTR1A
HTR2A)
business
Pharmacogenetics
medicine.drug
Zdroj: The Indian Journal of Medical Research
Indian Journal of Medical Research, Vol 142, Iss 1, Pp 40-45 (2015)
ISSN: 0971-5916
Popis: Background & objectives: Genetic factors have potential of predicting response to antidepressants in patients with major depressive disorder (MDD). In this study, an attempt was made to find an association between response to escitalopram in patients with MDD, and serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms. Methods: Fifty five patients diagnosed as suffering from MDD, were selected for the study. The patients were treated with escitalopram over a period of 6-8 wk. Severity of depression, response to treatment and side effects were assessed using standardised instruments. Genetic variations from HTR1A (rs6295), HTR2A (rs6311 and rs6313) and SLC6A4 (44 base-pair insertion/deletion at 5-HTTLPR) were genotyped. The genetic data of the responders and non-responders were compared to assess the role of genetic variants in therapeutic outcome. Results: Thirty six (65.5%) patients responded to treatment, and 19 (34.5%) had complete remission. No association was observed for genotype and allelic frequencies of single nucleotide polymorphisms (SNPs) among remitter/non-remitter and responder/non-responder groups, and six most common side-effects, except memory loss which was significantly associated with rs6311 ( p0 =0.03). Interpretation & conclusions: No significant association was found between the SNPs analysed and response to escitalopram in patients with MDD though a significant association was seen between the side effect of memory loss and rs6311. Studies with larger sample are required to find out genetic basis of antidepressant response in Indian patients.
Databáze: OpenAIRE
Externí odkaz: